利基迪亚重新提交的YUTREPIATM的NDA,这是一种治疗肺高血压的药物,被FDA接受,目标日期为5月24日. Liquidia's resubmitted NDA for YUTREPIA™, a treatment for pulmonary hypertension, is accepted by the FDA with a May 24 goal date.

液体公司的新药申请 (NDA) 提交 YUTREPIATM,一个吸入粉治疗肺动脉高血压和与间歇性肺病相关的肺高血压,已被FDA接受. Liquidia Corporation's New Drug Application (NDA) resubmission for YUTREPIA™, an inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, has been accepted by the FDA. 该机构已规定目标日期为2025年5月24日,供最后批准。 The agency has set a goal date of May 24, 2025, for final approval. 液体的重点是发展稀有心肺病的治疗方法。 Liquidia focuses on developing therapies for rare cardiopulmonary diseases.